Drug intelligence / Profile preview

SNP-820

Development stage: Phase 2
Lead developer: Sinew Pharma
Modality: Small Molecules
Administration: Oral

Overview

SNP-820 is a pharmaceutical antidote developed for the treatment of acetaminophen (paracetamol) poisoning. Its mechanism of action involves inhibiting liver enzyme activity to prevent the generation of toxic metabolites from acetaminophen that cause liver damage. It has received orphan drug designation from the Taiwan Food and Drug Administration (TFDA) and is in Phase II clinical trials for this indication. The efficacy of SNP-820 reportedly surpasses that of N-acetylcysteine, which is currently the standard treatment for acetaminophen overdose. The drug was developed by Sinew Pharma as a social welfare initiative due to its medical importance despite a limited market size[1][2][3][5].

Brand names: TYNADOTE
Other names: SNP 820SNP820SNP-820TYNADOTE

Targets

CYP1A2 (Cytochrome P450 1A2)CYP2E1CYP3A4 (Cytochrome P450 3A4)

Beyond the preview

Go deeper on SNP-820.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SNP-820.

Explore the full profile